Helixmith KOSDAQ:A084990 Stock Report Helixmith Co., Ltd
KOSDAQ:A084990 Stock Report
A084990 Stock Overview Develops biologic and natural nutraceutical products.
Rewards Risk Analysis See All Risk Checks Helixmith Co., Ltd Competitors Price History & Performance
Summary of all time highs, changes and price drops for Helixmith Historical stock prices Current Share Price ₩3,380.00 52 Week High ₩7,440.00 52 Week Low ₩3,250.00 Beta 1.08 11 Month Change -1.02% 3 Month Change -20.56% 1 Year Change -19.81% 33 Year Change -84.25% 5 Year Change -95.33% Change since IPO -77.22%
Recent News & Updates
Helixmith (KOSDAQ:084990) Is In A Good Position To Deliver On Growth Plans Oct 18 Helixmith Co., Ltd announced that it has received KRW 3.37919826 billion in funding Apr 26
Helixmith Co., Ltd announced that it expects to receive KRW 3.37919826 billion in funding Feb 06
New minor risk - Share price stability Dec 05 Helixmith Co., Ltd announced that it expects to receive KRW 9.999993078 billion in funding from CANARIABIO M Inc. Feb 09
Price target decreased to ₩19,900 Nov 29 See more updates
Helixmith (KOSDAQ:084990) Is In A Good Position To Deliver On Growth Plans Oct 18 Helixmith Co., Ltd announced that it has received KRW 3.37919826 billion in funding Apr 26
Helixmith Co., Ltd announced that it expects to receive KRW 3.37919826 billion in funding Feb 06
New minor risk - Share price stability Dec 05 Helixmith Co., Ltd announced that it expects to receive KRW 9.999993078 billion in funding from CANARIABIO M Inc. Feb 09
Price target decreased to ₩19,900 Nov 29
No independent directors Nov 16
Helixmith Co., Ltd(KOSDAQ:A084990) dropped from FTSE All-World Index (USD) Sep 19
Helixmith Announces Topline Results from Phase 2A Study of Engensis for Treatment of ALS (Amyotrophic Lateral Sclerosis) Sep 07
Helixmith Announces Topline Results from Double-Blind Placebo Controlled Multicenter Study for TADIOS Involving 100 Subjects Infected with COVID-19 Aug 04
First quarter 2022 earnings released: ₩335 loss per share (vs ₩92.65 profit in 1Q 2021) May 26
Price target increased to ₩29,182 Apr 28
Price target decreased to ₩26,529 Apr 27
No independent directors Apr 27
Price target decreased to ₩26,529 Dec 29
Helixmith Announces 50% Enrollment in Clinical Trial for COVID-19, Involving TADIOS Dec 02
Price target decreased to ₩33,000 Apr 16
New 90-day low: ₩24,550 Feb 24
Would Shareholders Who Purchased Helixmith's (KOSDAQ:084990) Stock Three Years Be Happy With The Share price Today? Feb 19
Wacker Chemie AG (XTRA:WCH) entered into an agreement to acquire Genopis Inc. from Medivate Partners LLC and Helixmith Co., Ltd (KOSDAQ:A084990) for $39 million. Feb 03
Helixmith Co., Ltd announced that it has received KRW 20 billion in funding Jan 23
Helixmith Co., Ltd announced that it expects to receive KRW 20 billion in funding Jan 22
Helixmith Co., Ltd has completed a Follow-on Equity Offering in the amount of KRW 161.25 billion. Dec 23
New 90-day low: ₩30,750 Oct 16
Helixmith to Be Deleted from Other OTC Oct 06
New 90-day low: ₩41,800 Sep 18
New 90-day low - ₩52,000 Aug 20
New 90-day low - ₩56,500 Jul 29 Shareholder Returns A084990 KR Biotechs KR Market 7D -8.6% 5.6% 0.8% 1Y -19.8% 46.2% 3.9%
See full shareholder returns
Return vs Industry: A084990 underperformed the KR Biotechs industry which returned 46.2% over the past year.
Return vs Market: A084990 underperformed the KR Market which returned 3.9% over the past year.
Price Volatility Is A084990's price volatile compared to industry and market? A084990 volatility A084990 Average Weekly Movement 5.9% Biotechs Industry Average Movement 8.5% Market Average Movement 5.4% 10% most volatile stocks in KR Market 11.4% 10% least volatile stocks in KR Market 2.6%
Stable Share Price: A084990 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A084990's weekly volatility has decreased from 11% to 6% over the past year.
About the Company Helixmith Co., Ltd develops biologic and natural nutraceutical products. The company offers LAYLA Tab for osteoarthritis; Allex and Allex i for hypersensitivity improvement; and Mnemosyne for memory improvement. Its lead gene therapy product is Engensis (VM202), which is in a phase III clinical trial for diabetic peripheral neuropathy and diabetic foot ulcer; a phase II clinical trial for amyotrophic lateral sclerosis (ALS) and claudication; and a phase I clinical trial for charcot-marie-tooth disease and coronary artery disease.
Show more Helixmith Co., Ltd Fundamentals Summary How do Helixmith's earnings and revenue compare to its market cap? A084990 fundamental statistics Market cap ₩155.64b Earnings (TTM ) -₩54.42b Revenue (TTM ) ₩3.17b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) A084990 income statement (TTM ) Revenue ₩3.17b Cost of Revenue ₩1.96b Gross Profit ₩1.21b Other Expenses ₩55.63b Earnings -₩54.42b
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -1.18k Gross Margin 38.05% Net Profit Margin -1,717.43% Debt/Equity Ratio 0.1%
How did A084990 perform over the long term?
See historical performance and comparison
Simply Wall St™ Simply Wall Street Pty Ltd Level 7, 320 Pitt Street, Sydney Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}